LifeVantage Corporation announced that Terrence Moorehead will become President and Chief Executive Officer effective August 5 2026, following the retirement of Steve Fife on April 30 2026. Moorehead brings more than 25 years of leadership experience in the direct‑selling and consumer‑products sectors, having previously served as CEO of Nature’s Sunshine Products from October 2018 to October 2025, where he grew revenue by 45 % and EBITDA by 190 %.
The transition will be overseen by interim CEO Michael Beindorff, who will lead the company from May 1 through August 4 2026, ensuring continuity as the board implements its long‑term strategy.
LifeVantage’s recent financial performance shows modest growth amid headwinds. In Q1 FY2026, revenue rose 0.7 % to $47.6 million, falling short of analysts’ estimate of $54.75 million. Net income per diluted share increased to $0.17 from $0.14, but EPS missed the consensus of $0.20. The miss reflects a revenue shortfall that outweighed the company’s cost‑control gains.
The company’s strategic focus remains on integrating the recently acquired LoveBiome, a microbiome‑based platform, and expanding its GLP‑1 activation portfolio. CEO Steve Fife highlighted that the acquisition positions LifeVantage at the intersection of two high‑growth wellness markets and that integration is already generating momentum across the business.
Chairman Raymond Greer praised Moorehead’s track record of scaling global health and wellness brands, noting that his expertise in sales, marketing, and finance will guide LifeVantage into its next growth phase. Greer emphasized that the search process was comprehensive and that Moorehead’s experience aligns with the company’s vision for accelerated growth and operational excellence.
The leadership change signals LifeVantage’s intent to strengthen its market position after a year of declining stock value and challenging revenue dynamics. With Moorehead’s proven ability to drive growth at Nature’s Sunshine and other brands, the board expects renewed focus on product innovation, consultant network expansion, and strategic partnerships to counter competitive pressures from GLP‑1 hormone drugs and other wellness competitors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.